Gyre Therapeutics, Inc. filings document a commercial-stage biopharmaceutical issuer with U.S. and China operations, revenue from Gyre Pharmaceuticals, and a pipeline centered on anti-fibrotic therapies and targeted protein degradation assets. Form 8-K reports cover operating results, business updates, CDE/NMPA regulatory disclosures for F351, and clinical-program updates for Hydronidone and pirfenidone.
Proxy and material-event filings describe governance matters, shareholder voting items, material agreements, capital-structure disclosures and the completed Cullgen acquisition, including preferred-stock and common-stock conversion mechanics. The record also includes Regulation FD disclosures addressing commercial products, research spending and pipeline development.
Gyre Therapeutics, Inc. (GYRE) released an updated corporate presentation describing a global, protein-degrader–focused biotech strategy anchored by China-based discovery and commercialization and a U.S. headquarters in San Diego. The company highlights a flexible model in which China revenue and infrastructure support early R&D, while U.S. capital funds priority global clinical programs.
For fiscal 2026, Gyre provides total revenue guidance of $100–$111 million, with China commercial products funding much of its early-stage pipeline. Lead fibrosis asset F351 (hydronidone) has an NDA filing for chronic hepatitis B–induced liver fibrosis accepted by China’s NMPA in May 2026, with a potential launch in early 2027. Phase 3 data show ≥1‑stage fibrosis regression at Week 52 in 52.85% of F351 patients versus 29.84% on placebo (p=0.0002), and ≥1‑grade inflammation improvement without fibrosis progression in 49.57% versus 34.82% (p=0.0246).
The presentation also details a diversified degrader and DAC pipeline: CDK2/Cyclin E degrader CG923308 and TYK2/JAK1 degrader CG620953 targeting oncology and autoimmune diseases with planned IND submissions in Q1 2027; pan‑TRK degrader CG001419 with completed Phase 1 and planned Phase 2 for cancer‑induced bone pain; and GSPT1 degrader CG009301 in an ongoing Phase 1 trial in high-risk hematologic malignancies. Gyre positions its Degrader Antibody Conjugate platform as a next-generation approach building on both ADC and targeted protein degrader technologies.
Gyre Therapeutics, Inc. (GYRE) filed an 8-K to furnish an updated corporate presentation outlining its strategy as a global development engine combining U.S. leadership with China-based discovery, development and commercialization.
The presentation highlights an established China commercial franchise anchored by pirfenidone for idiopathic pulmonary fibrosis, with FY26 total revenue guidance of $100.5–$111 million, intended to help fund a diversified R&D pipeline. The lead China asset F351 (hydronidone) for CHB-induced liver fibrosis has an NDA accepted by the China NMPA, supported by Phase 3 data showing materially higher fibrosis regression and inflammation improvement versus placebo, with potential launch in early 2027.
Gyre describes a broad pipeline of targeted protein degraders and Degrader Antibody Conjugates across oncology, autoimmune disease and pain, including CDK2/Cyclin E, TYK2/JAK1, pan-TRK and GSPT1 degraders, with multiple preclinical and early clinical catalysts planned around 2027.
Gyre Therapeutics, Inc., a commercial-stage biopharmaceutical company, reported revenue of $29,105 and $53,535 for the three and six months ended June 30, 2026, respectively (amounts in thousands). On May 4, 2026 it completed a common-control merger with Cullgen Inc., now a wholly owned subsidiary, and earlier periods have been retrospectively recast.
Operating expenses reached $43,468 in the quarter, including research and development of $14,300, related-party R&D of $4,836, selling and marketing of $13,754, and general and administrative of $7,867, plus transaction costs. Net loss attributable to common stockholders was $11,663 for the quarter and $24,809 year-to-date, compared with a $2,044 net loss and $126 of net income in the comparable 2025 periods, with basic and diluted loss per share of $0.12 and $0.26 for the three- and six‑month periods. Cash and cash equivalents were $43,287, alongside short-term bank deposits, short-term investments, and long-term certificates of deposit that supported total assets of $199,255 and equity of $142,489. Management states that existing liquidity, operating cash flows, and access to capital markets are expected to fund operations for at least twelve months. Revenue is concentrated in mainland China, with Sinopharm and two other distributors accounting for most pharmaceutical product sales, and a single partner generating all collaboration-based revenue.
Gyre Therapeutics reported Q2 2026 revenue of $29.1 million, down 2% from Q2 2025, and GAAP basic EPS of $(0.12). Net loss widened to $14.3 million from a $2.2 million loss, while non-GAAP adjusted net loss was $12.2 million versus $0.6 million a year earlier.
For the first half of 2026, revenue was $53.5 million compared with $60.3 million in 2025, with net loss of $32.8 million versus net income of $2.7 million. Cash, deposits, investments and long-term certificates of deposit totaled $103.2 million as of June 30, 2026. Financial statements were retrospectively recast to treat Gyre and Cullgen as entities under common control.
Key developments included completion of an all-stock acquisition of Cullgen valued at about $300 million, acceptance by China’s CDE of the NDA for F351 for CHB-induced liver fibrosis, continued growth of pirfenidone sales to $28.0 million in Q2, and expanded R&D spending, including F351 Phase 3C costs and milestone payments.
Gyre Therapeutics director Claire Weston received a grant of stock options to purchase 40,000 shares of common stock at an exercise price of $6.11 per share. The options vest in 36 equal monthly installments through August 3, 2029 and expire on August 3, 2036, leaving her with options on 40,000 shares.
Gyre Therapeutics director Kirkby Maxwell received a grant of stock options covering 40,000 shares of common stock on August 3, 2026. The options have a $6.1100 exercise price, expire on August 3, 2036, and vest in 36 equal monthly installments through August 3, 2029, subject to continued service.
GYRE THERAPEUTICS, INC. filed an initial Form 3 reporting the beneficial ownership status of director Weston Claire. The report lists Weston Claire as a director but shows no reported transactions or share holdings at this time. The remarks reference Exhibit 24, a Power of Attorney authorizing filings.
Gyre Therapeutics, Inc. reported an initial statement of beneficial ownership for Kirkby Maxwell. He is identified as a director, not an officer or 10% owner, and currently has no reportable securities holdings or transactions. Remarks reference an Exhibit 24 Power of Attorney.
Gyre Therapeutics, Inc. appointed three new members to its board of directors, effective August 1, 2026: Yue Xiong, Ph.D., the company’s Chief Scientific Officer, as a Class I director; Maxwell Kirkby as a Class II director; and Claire Weston, Ph.D., as a Class III director. Mr. Kirkby joins the Compensation Committee and Dr. Weston joins the Audit Committee. Mr. Kirkby and Dr. Weston each receive an initial stock option grant covering 40,000 shares of common stock, vesting in equal monthly installments over three years, plus cash compensation under the non-employee director policy. Dr. Xiong, who already serves as Chief Scientific Officer and is party to the standard indemnification agreement, will receive no additional compensation for board service.